Trientine-induced neurological deterioration in a patient with Wilson's disease
- Authors
- Kim, Bomi; Chung, Sun Ju; Shin, Hae-Won
- Issue Date
- Apr-2013
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Brain MRI; Neurological deterioration; Trientine; Wilson's disease
- Citation
- JOURNAL OF CLINICAL NEUROSCIENCE, v.20, no.4, pp 606 - 608
- Pages
- 3
- Journal Title
- JOURNAL OF CLINICAL NEUROSCIENCE
- Volume
- 20
- Number
- 4
- Start Page
- 606
- End Page
- 608
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/14741
- DOI
- 10.1016/j.jocn.2012.02.041
- ISSN
- 0967-5868
1532-2653
- Abstract
- Trientine (triethylenetetramine dihydrochloride) is a copper-chelating agent used to treat patients with Wilson's disease (WD). It has been considered safe, rarely causing neurological deterioration during initial treatment. We describe a patient diagnosed with WD who became neurologically disabled after treatment with trientine. On a fluid attenuated inversion recovery sequence, brain MRI showed increased areas of high signal intensity compared with initial brain MM. The patient's neurological signs partially resolved after cessation of trientine treatment. Our findings suggest that treatment with trientine is associated with a risk of neurological deterioration in patients with WD. (C) 2012 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/14741)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.